The U.S. FDA’s new draft guidance for the voluntary incorporation of patient preference information (PPI) in device development says that PPI would be included in product labels for cleared or ...
AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a three-part Phase 1 clinical trial and a Phase 2 open label extension trial in patients with ...